我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
12
1 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
7
58.3%
Enrolling By Invitation
1
8.3%
招募中
终止
2
16.7%
Unknown
暂无批准数据
- The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved the first-ever human trial of regenerative cell therapy for sensorineural hearing loss, marking a significant milestone in auditory medicine. - Rinri Therapeutics' Rincell-1 therapy is designed to regenerate damaged auditory neurons, targeting a condition for which no current treatment exists beyond symptom management. - The randomized, open-label trial will involve 20 patients across three UK research centers, with clinical proof-of-concept data expected within 12 months of trial initiation. - The therapy represents a potential breakthrough for treating neural hearing loss by replacing damaged sensory cells in the inner ear to restore hearing function.
